Pravastatin-induced dermatomyositis;Dermatomyosite induite par la pravastatine

Revue de Medecine Interne

Volumn 26, Issue 11, 2005, Pages 897-902

  Zuech, P ^a   Pauwels, C ^a   Duthoit, C ^b   Mery L ^a   Somogyi, A ^a   Louboutin, A ^a   Veyssier Belot, C ^a  

^a CENTRE HOSPITALIER INTERCOMMUNAL   (France)

^b Dermatologue   (France)

Author keywords

Cutaneous reactions to drugs; Dermatomyositis; Side effects of drugs; Statins

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN;

AGED; ARTICLE; CASE REPORT; CAUSE OF DEATH; DERMATOMYOSITIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; HUMAN; LONG TERM CARE; LUNG FIBROSIS; POLYMYOSITIS; RESPIRATORY FAILURE; SKIN MANIFESTATION; SYMPTOMATOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS;

AGED; ANTICHOLESTEREMIC AGENTS; DERMATOMYOSITIS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; PRAVASTATIN; TIME FACTORS;

EID: 27844500183     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2005.07.005     Document Type: Article

References (26)

1. P.D. Thompson, P. Clarkson, and R.H. Karas Statin-associated myopathy JAMA 289 2003 1681 1690
2. S. Guis, J.P. Matt́i, and F. Liot́ Drug-induced and toxic myopathies Best Practise and Research Clinical Rheumatology 17 2003 877 907
3. O. Ziegler, and P. Droin Safety, tolerability and efficacy of simvastatin and fenofibrate Cardiology 77 1990 50 57
4. L. Rudski, M.A. Rabinovitch, and D. Danoff Systemic immune reactions to HMG-CoA reductase inhibitors. Report of four cases and review of the literature Medicine 77 1998 378 383
5. P.-E. Stoebner, C. Michot, C. Ligeron, L. Durand, J. Meynadier, and L. Meunier Lichen plan pemphigöde induit par la simvastatine Ann. Dermatol. Venereol. 130 2003 187 190
6. M. Srivastata, A. Rencic, G. Diglio, H. Santana, P. Bonitz, and R. Watson Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus Arch. Dermatol. 139 2003 45 49
7. I.W. Graziadei, G.E. Obermoser, N.T. Sepp, K.H. Erhart, and W. Vogel Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis Lupus 12 2003 409 412
8. A.-L. Fauchais, J. Iba Ba, P. Maurage, X. Kyndt, D. Bataille, and E. Hachulla Polymyosites induites ou assocíes aux traitements hypoliṕmiants? ̀ propos de cinq cas Rev. Med. Interne 25 2004 294 298
9. B.B. Schalke, B. Schmidt, K. Toyka, and H.-P. Hartung Pravastatin-associated inflammatory myopathy N. Engl. J. Med. 327 1992 649 650
10. F.H. Khattak, I.M. Morris, and W.A. Brandford Simvastatin-associated dermatomyositis Br. J. Rheumatol. 33 1994 199
11. C. Hill, C. Zeitz, and B. Kirkham Dermatomyositis with lung involvement in a patient treated with simvastatin Aust. N. Z. J. Med. 25 1995 745 746
12. J. Rodriguez-Garcia, and M. Serrano Commino Lovastatin-associated dermatomyositis Postgrad. Med. J. 72 1996 694
13. B. Nöl, J.-P. Cerottini, and R.G. Panizzon Atorvastatin-induced dermatomyositis Am. J. Med. 110 2001 670 671
14. A. Takagi, and Y. Shiio [Pravastatin-associated polymyositis, a case report](article en japonais) Rinsho Shinkeigaku 44 2004 25 27
15. O.M. Vasconcelos, and W.W. Campbell Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake Muscle Nerve 30 2004 803 807
16. N. Thual, K. Penven, J. Chevallier, A. Dompmartin, and D. Leroy Dermatomyosite induite par la fluvastatine. Jourńes dermatologiques de Paris 2004, poster 228 Ann Dermatol Venereol 131 2004 ([hors śrie 1]:: 1S212)
17. A. Bohan, J.B. Peter, R.L. Bowman, and C.M. Pearson Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis Medicine 56 1977 255 286
18. B.A. Masters, M.J. Palmoski, O.P. Flint, R.E. Gregg, Wang-Iverson, and S.K. Durham In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin and simvastatin, using neonatal rat skeletal myocytes Toxicol. Appl. Pharmacol. 131 1995 163 174
19. M. Bigby Rates of cutaneous reactions to drugs Arch. Dermatol. 137 2001 765 770
20. T. Vial, B. Nicolas, and J. Descotes Drug-induced autoimmunity: experience of the French Pharmacovigilance system Toxicology 119 1997 23 27
21. B. B́gaud, J.C. Evreux, J. Jouglard, and G. Lagier Imputabilit́ des effets inattendus ou toxiques des medicaments. Actualisation de la ḿthode utiliśe en France Therapie 40 1985 111 118
22. Machet L, Lavigne C, Rivollier C. Dermatomyosite. Encycl. Méd. Chir. (Editions Scientifiques et Médicales Elsevier SAS, Paris, tous droits réservés), Dermatologie, 98-500-A-10, 2003, 12p.
23. I. Marie, E. Hachulla, P.Y. Hatron, M.F. Hellot, H. Ĺvesque, and B. Devulder Polymyositis and dermatomyositis: Short term and long term outcome, and predictive factors of prognosis J. Rheum. 28 2001 2230 2237
24. B.A. Phillips, P. Zilko, M.J. Garlepp, and F.L. Mastaglia Frequency of relapses in patients with dermatomyositis and polymyositis Muscle Nerve 21 1998 1668 1672
25. M. Andŕjak, V. Gras, Z.A. Massy, and J. Caron Effets ind́sirables des statines Therapie 58 2003 77 83
26. B. Nöl Autoimmune disease and other potential side-effects of statins Lancet 363 2004 2000